Gonadotrophin releasing hormone (GnRH) receptor and steroid receptors in human uterine leiomyoma, myometrium and endometrium

International Journal of Oncology

Volumn 11, Issue 3, 1997, Pages 603-607

  Reshkin, Stephan J ^a,b,c   Albarani, Valentina ^b   Pezzetta, Antonia ^b   Marinaccio, Marco ^a   Paradiso, Angelo ^b  

^a UNIVERSITY OF BARI   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c Institute of General Physiology   (Italy)

Author keywords

GnRH; Leiomyoma; Steroid receptors; Uterus

Indexed keywords

ESTROGEN RECEPTOR; GONADORELIN; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GOSERELIN; PROGESTERONE RECEPTOR; STEROID RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM; FEMALE; HUMAN; HUMAN TISSUE; MYOMETRIUM; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; TISSUE DISTRIBUTION; UTERUS MYOMA;

EID: 0030757329     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.11.3.603     Document Type: Article

References (27)

1. John AMH and Martin R: Growth of leiomyomata with estrogen progesterone therapy. J Reprod Med 6: 49-55, 1971.
2. Marugo M, Centonze M, Bernasconi D, Fazzuoli L, Berta S and Giordano G: Estrogen and progesterone receptors in uterine leiomyomas. Acta Obstet Gynecol Scand 68: 731-735, 1989.
3. Rein MS, Friedman AJ, Stuart JM and MacLaughlin DT: Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate. Fertil Steril 53: 1018-1023, 1990.
4. Lumsden MA, West CP and Baird DT: Goserelin therapy before surgery for uterine fibroids. Lancet 1: 36-37, 1987.
5. Kessek B, Liv J, Mortola J, Berga S and Yen SSC: Treatment of uterine fibroids with agonist analogs of gonadotropin-releasing hormone. Fertil Steril 49: 538-541, 1988.
6. West CP, Lumsden MA, Lawson S, Williamson J and Baird DT: Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot. Fertil Steril 48: 45-51, 1987.
7. Vercellini P, Fedele L, Arcaini L, Bianchi S, Sideri M and Candiani GB: Trattamento dei leiomiomi uterini e della menorragia con goserelin depot. In: Analoghi agonisti dell'LH-RH: impieghi clinici attuali e prospettive future. The Parthenon Publishing Group, Carnfoth, pp75-85, 1990.
8. Friedman AJ, Hoffman DJ, Comite F, Browneller RW and Miller JD: Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. Obstet Gynecol 77:720-725, 1991.
9. Letterie GS, Coddington CC, Winkel CA, Shawker TH, Loriaux DL and Collins RL: Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up. Fertil Steril 51: 951-956, 1989.
10. Malta WH, Shaw RW and Nye M: Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab 67: 701-706, 1988.
11. Sandow J: Pharmacology of LH-RH agonists. In: Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action. Furr BJA and Wakeling AE (eds). Bailliere Tindail, London, PP365-384, 1987.
12. Fraser HM, Bramley TA, Miller WR and Sharpe RM: Extra pituitary actions of LHRH analogues in tissues of the human female and investigation of the existence and function of LHRH-like peptides. Prog Clin Biol Res 225: 29-33, 1986.
13. Guerrero HE, de Fried EP, Stein P, Tesone M and Asch RH: Effect of a gonadotropin-releasing hormone agonist on luteinizing hormone receptor and steroidogenesis in ovarian cells. Fertil Steril 59: 803-809, 1993.
14. 6]-luteining hormone-releasing hormone, somatostatin, epidermal growth factor and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 3: 137-147, 1989.
15. Eidne KA, Flanagan CA and Miller RP: Gonadotropin-releasing hormone bilding sites in human breast carcinoma. Science 229: 989-991, 1985.
16. 6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 50: 1841-1846, 1990.
17. Nakano R, Kitayama S and Yamamoto M: Localization of gonadotropin binding sites in human ovarian neoplasms. Am J Obstet Gynecol 161: 905-909, 1989.
18. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye-binding. Anal Biochem 72: 248-254, 1976.
19. 3H-GnRH method for the measurement of GnRH binding sites in human breast cancer and breast cancer cell lines. Int J Oncol 7: 371-375, 1995.
20. Scatchard G: The attractions of proteins for small molecules and ions. Ann NY Acad Sci 51: 660-672, 1949.
21. Piffanelli A, Pelizzola D, Giovannini G, Catozzi L, Faggioli L and Giganti M: Characterization of laboratory working standards for quality control of immunometric and radiometric estrogen receptor assays. Tumori 75: 550-556, 1989.
22. Wiznitzer A, Marbach M, Insler V, Sharoni Y and Levy J: Gonadotropin-releasing hormone specific binding sites in uterine leiomyomata. Biochem Biophys Res Commun 152: 1326-1331, 1988.
23. Neuman M, Langer R, Golan A, Bukovsky I, Caspi E and Koch Y: Gonadotropin-releasing hormone (GnRH) action on uterine leiomyomata is not mediated by uterine GnRH receptors. Fertil Steril 56: 364-366, 1991.
24. Phawa GS, Kullander S, Vollmer G, Oberheuser F, Knuppen R and Emons G: Specific low affinity binding sites for gonadotropin-releasing hormone in human endometrial carcinomata. Eur J Obstet Gynecol Reprod Biol 41: 135-142, 1991.
25. 1-in human breast cancer in vivo following tamoxifen treatment. Cancer. Res 52: 4261-4264, 1992.
26. Irmer G, Bürger C, Müller R, Ortmann O, Peter U, Kakar SS, Neill JD, Schulz K-D and Emons G: Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. Cancer Res 55: 817-822, 1995.
27. Waring DW and Turgeon JL: A pathway for luteinizing hormone releasing-hormone self-potentiation: cross-talk with the progesterone receptor. Endocrinology 130: 3275-3282, 1992.